This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Feb 6;145(6):551-552.

doi: 10.1182/blood.2024027064.

Asciminib for Ph+ ALL: a step forward?

Fabian Lang¹, Oliver G Ottmann²

Affiliations

PMID: 39913337
DOI: 10.1182/blood.2024027064

Editorial

Asciminib for Ph+ ALL: a step forward?

Fabian Lang et al. Blood. 2025.

. 2025 Feb 6;145(6):551-552.

doi: 10.1182/blood.2024027064.

Authors

Fabian Lang¹, Oliver G Ottmann²

Affiliations

¹ Goethe University Hospital.
² Cardiff University.

PMID: 39913337
DOI: 10.1182/blood.2024027064

No abstract available

PubMed Disclaimer

Comment on

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Luskin MR, Murakami MA, Keating J, Flamand Y, Winer ES, Garcia JS, Stahl M, Stone RM, Wadleigh M, Jaeckle SL, Hagopian E, Weinstock DM, Liegel J, McMasters M, Wang ES, Stock W, DeAngelo DJ. Luskin MR, et al. Blood. 2025 Feb 6;145(6):577-589. doi: 10.1182/blood.2024025800. Blood. 2025. PMID: 39374521 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems